Managing Male OAB: Update for the APP Webinar (2025)
Availability
No future session
Expires on Nov 13, 2028
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credit Credits
1.5 Participation Credits
EDU-25-6534 Webinar Marketing 1200 x 148
The American Urological Association is proud to offer Managing Male OAB: Update for the Advanced Practice Provider, a dynamic educational activity, featuring a multidisciplinary panel of experts, including a nurse practitioner, physician assistant, and urologist, that will build upon the success of previous AUA education in OAB. Based on the documented educational need, the AUA will update APPs on the latest advancements in the management of patients with OAB, specifically OAB associated with Benign Prostatic Hyperplasia (BPH).

ACKNOWLEDGEMENTS

Support provided by an independent educational grant from:

  • Sumitomo Pharma America, Inc.
  • APPs
After participating in this CME activity, participants will be able to:

  1. Counsel and treat patients with OAB by incorporating current evidence on its epidemiology, burden and association of OAB in men with BPH.
  2. Integrate into practice the principles for diagnosis, counseling and treatment of OAB based on the clinical recommendations from the 2024 AUA/SUFU Guideline including the application of the Guideline to men with OAB associated with BPH.
  3. Implement OAB treatment strategies that incorporate evidence-based knowledge and patient centered considerations, including efficacy and side effects of treatment.
  4. Differentiate OAB medications based on mechanisms of action, side effects, and contraindications.
  5. Evaluate and apply emerging evidence of the association of antimuscarinic medications with cognitive decline, especially in the frail patients with OAB, into clinical decision making.
Name Company Name Relationship Type End Date
Hughes, Corinna No relevant financial relationships to disclose
Mogil, Adam G. No relevant financial relationships to disclose
Nitti, Victor William Bright Uro Consultant or Advisor Current
EG 427 Consultant or Advisor Current
Abbvie Consultant or Advisor Current

EDUCATION COUNCIL DISCLOSURE

Education Council Disclosures

COI REVIEW WORK GROUP DISCLOSURES

COI Review Workgroup Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Welcome and Introductions

Pre-test

Segment 1: OAB in Men with BPH: Insights from the 2024 AUA/SUFU Guideline

Segment 2: Clinical Evaluation – Differentiating Voiding vs. Storage Symptoms

Segment 3: Management Pathway for Storage + Voiding Symptoms

Segment 4: Medication Strategy—Evidence, Comfort, and Combination Therapy

Segment 5: Advanced & Procedural Options

Post-test

Wrap-up

AUA ACCREDITATION INFORMATION

ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Attendee Information & Policies

AUA Anti-Harassment Policy

AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms. 

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA. 

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.